Transperineal versus transrectal multi-parametric magnetic resonance imaging fusion targeted prostate biopsy

Article Figures & Data

Table 1

- Distribution of different parameters across both biopsy strategies.

Parameters	TRUSBx (n=165)	TPBx (n=142)	P-value
Age (mean±SD)	51-80 years (65.1±7.8)	47-80 years (65±8.5)	0.8
Prostate-specific antigen	3.5-26 ng/ml (14.2±5)	4-222 ng/ml (13.7±25.9)	0.4
Prostate volume	31-170 cc (61.9±34.9)	26-196 cc (63±22)	0.7
Obesity (BMI>30) (%)	25 (15.15)	24 (16.9)	0.6
Prior prostate biopsy with negative finding (%)	23 (14)	12 (8.4)	0.6
Present positive DRE (%)	15 (9)	14 (9.8)	0.8
Number of lesions
PI-RADS 3	35	30	0.7
PI-RADS 4	19	25
PI-RADS 5	16	20

BMI: body mass index, DRE: digital rectal examination, PI-RADS: prostate imaging reporting and data system, TRUSBx - transrectal ultrasound-guided biopsy, TPBx: transperineal biopsies

Table 3

- Comparison of TRUSBx and TPBx regarding procedure’s cancer detection rate, and duration of the procedure.

Parameters	TRUSBx (n=165)	TPBx (n=142)	P-value
Cancer detection rate	48 (29.1)	64 (45.1)	0.003
Clinically significant cancer detection rate
PI-RADS 3	2 (9.5)	1 (2.1%)	0.05
PI-RADS 4	7 (33.3)	20 (43.4.1%)
PI-RADS 5	12 (57.1)	25 (54.3%)
Total	21 (43.7)	46 (71.8%)	0.002
Operation duration (mean±SD)	13±2.3	41.2±0.7	0.0001

Values are presented as number and percentage (%). TRUSBx: transrectal ultrasound-guided biopsy, TPBx: transperineal biopsies, SD - standard deviation.